From Barchart: 2025-05-13 07:00:00

Waldencast plc (NASDAQ:WALD) is a skincare company founded in 1988, offering treatments for skin aging, damage, hyperpigmentation, acne, and sun damage. They distribute products through dermatologists, plastic surgeons, and medical spas, with brands like Obagi Medical and Obagi Clinical focusing on improving skin tone and texture.

Despite a stable short-term price target of $5, Waldencast’s financial performance has been strong. In Q4 2024, they reported a net revenue of $72.1 million, a 29.4% growth, and an adjusted EBITDA of $11.2 million, doubling from Q4 2023. D.A. Davidson has set a higher price target of $15.50 due to this impressive performance.

In Q3 2024, Waldencast saw significant growth with net revenue of $70.2 million, a 34.6% increase. Brands like Obagi Medical and Milk Makeup contributed to this growth, with revenue increases of 45.5% and 23.5%, respectively. Adjusted EBITDA for Q3 was $11.4 million, a 134% increase from the previous year.

In Q2 2024, Waldencast reported a net revenue of $63.3 million, a 25.7% increase. Brands like Obagi Medical and Milk Makeup saw revenue growth of 30.9% and 20.0%, respectively. The adjusted EBITDA rose by 64.5% to $6.3 million, contributing to the positive outlook and higher price target set by D.A. Davidson.



Read more at Barchart:: Waldencast plc (NASDAQ:WALD) Demonstrates Strong F…